

From the Office of Clinical Informatics Cerner Millennium Using Pharmacy Patient Monitor September 8, 2023

The Pharmacy Patient Monitor (PPM) is a pharmacist centered view within PowerChart that displays patients who have orders on their profile that need Pharmacy interaction, such as verification. This flyer outlines how to use PPM to verify future and activated orders.

Verifying Day of Treatment Orders

When patients are in the infusion clinic for treatment, pharmacists will verify medications activated by the nurse. To do this, the pharmacist will monitor the activated orders queue in PPM.

- Pharmacy Patient Monitor
 - From **Pharmacy Patient Monitor (PPM)**, select the appropriate view for activated orders to verify.



• Click the patient demographic box to open order details to the right.

<u>NOTE</u>: Clicking the patient's name opens the chart to review dosing weight, lab results, etc.

- The **Inpatient Orders** section displays order(s) requiring verification.
 - Click **Process** to verify all orders listed.
 - To only verify certain medications, select the applicable order(s), then click **Process**.
- This opens **Pharmacy MedManager** to complete processing.

Rew; Brewer Onc Future v	1 m 370 🎼 🗘	TRAIN, ONCCLINA	NRN: 9300330 DOB: 07/17/1973 Age: 50 years Sux: Female Weigh	it 70 kg
All - Q		▼ Inpatient Orders		bow 0
TRAIN, ONCCLINA - 50 years Hern: ISSOECO	Quesue time: 52 days D08: 87/17/1573	 Antiemetic St 	atus Maintain at baseline, MODerate on Dey(s) 1, Low on Dey(s) 2-3, <, Plasmacy to H Statiss: Februe Ro printlty: Routine	lange, 12 fr., Days 1 fo 3 Queste lines: 12 days State: 24 days
TRAIN, ONCCLINE - 30 years HINI 330331	Queue lime: 52 days DOI: 67/17/1973	 toposide 14: 560 mL/hr, Infur 	5 mg + Overfill Volume (approx.) 51 ml. + Sodium Chloride 0.9%(Intermitt iz Over: 1 br Status Febre Ra proxity: Rodine	tent) 500 mL (s0 mglm2), 5m, 1/45, Day of 7s, Long cance, Rustine, "Ext. 57(15/23, "Ext. 67/21/23, Future Order, Days 1 to 3, Rate: Quence time: 52 days Set an SetVice: SetVice222 22:00:00 EVT
TRAIN, ONCOLINC - 50 years	Queset Unter 52 days (XCR: #27/17/1973	 CARBOplatin 	575 mg + Overfill Volume (approx.) 31 ml. + Sodium Chloride 0.9%(Intern Schwer Ruhme Ro grindly: Rautine	mittent) 250 mL (AUC 5), Solin, 1499, Day of Tis, Lang cancer, Rautine, 07(21)/23, Pubrie Order, Days J, Rater 258 mL/kr, Jankas Overs 1 i Queues time: 52 April Stand: datafiliare (MMR)2022 250608 EDT
DINC / 4G4CA LEAD, ONCE - 50 years HIN 9300187	Quese time: 51 days Octo: 67/17/1593	 pegfilgrastim dexAMETHas 	Not Indicated EA, Days 1 Soften Patrie Its priority Rautine ane (Decadron) 12 ms. Tak-Po, Dier of Tu, Lung Lencer, Restine, 07/21/23, Peters Orde	Quéces Times 52 daya Sourt care/Times (96/98/2022 22:40 de EDT
R. CARER CARE BREVEN HED ONC / ONC.E LEAD, ONCA - 50 years HEN: 9300186	Quesue time: 51 days DOI:: 67/17/1973	 palonosetron 	Statum Peture F3 pileffin Routine (Akoat) 0.23 mg, Sein, JVPB, Day of Tx, Lung cancer, Routine, 07/21/23, Puture Order, Day	Queue Inst. 12 dates Start data/Inst. (90/09/2022 22:00:00 EDT vs 3. Influe Over: 20 House
R. CANCER. CARE BREWER HED ONC / DNC_E TRAIN, ONCCLINNN - 50 years min: 9300269	Quese fine: 51 drys DOI: 87/17/1973	0*	Status Puture Ru printly: Radine	Queue time 52 dan Sket uler/live: 04/94/2023 22:00:00 EDT View Process

Encounter Selection

- Select the appropriate encounter for the type of orders being verified.
 - When verifying activated day of treatment orders, select the **Recurring** encounter for the appropriate location.
 - When verifying future orders, select the **Clinic** (or Inpatient) encounter for the location they were placed on.
- Many orders will have a **Parent** order which includes the **Child** orders. Be sure to verify the **Parent** order.
- Select **Apply** to continue verifying.

Product Selection

- After selecting Apply, the **Product Selection** window displays for the first medication to verify.
- Review the medication(s) in the ingredient window and select the appropriate product in the lower left pane. Once a product has been selected, click Move.
 - When finished select **OK**.
- When there are multiple ingredients in the order, also known as an **IV Set**, each ingredient is listed in the ingredients section.
- Review each of the items listed and select the appropriate product in the lower left pane and click **Move**.
- Once all the products have been assigned, click **OK**.
- The Verify Intermittent Protocol window displays. Review the details, make any updates as needed, and click OK.
- Follow the same process for all remaining orders.
- Dosage Calculator
 - The Dosage Calculator icon a will display for medications that require weight-based dosing.
 - The **Dosage Calculator** is a tool used to calculate actual medication doses from a normalized dose based on a patient's actual weight, a calculated weight, body surface area (BSA) or area-under-the-curve (AUC) target dose.
 - Select the **Dosage Calculator** icon \mathbf{s} to view if there was a dose reduction done by the provider.
 - Continue verifying all the remaining orders.
 - Once all orders have been reviewed, the list of orders display in MedManager.
 - Click **Submit**.

gredients:			Last updated by:		Communic	cation type:		
CARBOplatin	540 mg	^	TRAIN, PHYS ONCOLOG	3Y01 - Phys Oncology p2	Written			
CARBOplatin			Order comments:					
Sodium Chloride 0.9%	250 mL	~						$\hat{}$
ε		>						
Filter Options			Liser defined details					
All Routes and Dosage Forms	Linked P	roducta	Target Dose: (AUC 5)					~
O Route / Dosage Form compatible								
Ordered Dosage Form								5
n i i m luce ml			Selected products:					
Products (1) [1/ Sets (0)]		1	Product	Dose	Unit	DapOly	QtyUnt	-
Description	Prod Info							
CABBOolatio 50mm / 5ml JNJ	50 ma /5 ml. S	olo I						
		Mo						
						17245	0	1

Chug										E	Update
4 CSD Vel	Drug	0		Dose				Ordered As		1	Renne
4 12	CAF	RBOplatin		540 m	g/54 mL 5 A	UC(Carboplate)]	- 16	CARBOplatin	_		
	01	C4RBOptat	in 60mg / Sm	ILINJ				Protect Children D. Ch.	that 1		Math.
	64	Section Ch	locite (19%)	NJ 25eril 19	CHL			account criteriae p.v.	-00a.	124	CELEVILLE THE
4 2	Ove	edil Volume	(approx.)	31 mL				Overfill Volume (appro	0K.)	aread	and undares
	dis"	Overfill Volk	ame (approx.) (PB)						335	
Rinde					D DEDN dow	POINT PRIMA		*p	-		
VPB	V Daw of Ta		- 60 C	iaton.	111111000	(Norse)		TR	AN PHYS	ONEC	LOGY30
*Rate			10 tota	a cher							
335	niuter	4	1	hr	÷						
						Sings chain		Time EDT	Disper	-	
0	Nanei		00/10/202	13 1.	05.16	09/10/20		÷ + 0516 ÷	Physic	un Si	84
vevious sched	over administration	ion:	Téret.edm		54	p Followre		Skip	Rent		doies:
	÷ -	- 171			-	acastation .		1 1 1			
				-	Land .			4.51 .45			
Juder constrer	ets:										
					0	CHEMOTHERAPI	EUTIC	AGENT			-
					~ ~	CHEMOTHERAPI	EUTIC	AGENT			-
inste oim:			Communical	tion type:		CHEMOTHERAPI	EUTIC	AGENT			Product
Smage toim:			Communical Writien	ion type:	2 2	Drde prorie Reden prorie Reden	EUTIC	AGENT			Product.
Sosago loim: Soln Dispense cata	egoty	~	Communical Writen Disperve fro	lian type: m location:	×	Product notes: CHEMOTHERAPI Driles proving Routine Instal doses:	EUTIC.	AGENT			Product.
Insage form: Sofn Dispense zate CHEMO-WPB	agoty	> 6 6	Communical Written Disperate tro	tion type: im location scology Bree	v v ver Phar v Ø	Product notes: CHEMOTHERAPY Drdes procely Routine Initial doses: 1	EUTIC.	AGENT			Poduct. Pentrop
Sonago loire: Soln Dispense cata CHEMO-MPB Billing formula	agoty 4		Communical Witten Dispanae tro E Medical Or Dart dispana	iontype: milocation cology Breve e data T	ver Phas - @	Product notes: CHEMOTHERAPI Drdes: proving Routine Initial doses: 1	EUTIC	AGENT		6	Product. Feating Connection Order Type
Jassago loim: Soln Dispense tata CHEMO-WPB Billing farmula Non Pasa The	egory e Sugh	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Communicat Written Disperse fo Dist disperse Ipagette	lion type: millionation cology Breve e date t t t t t t	v aur Phas v to tome	Drdwctodes: CHEMOTHERAPP Drdw provin Routice Tritel doses 1	EUTIC.	AZENT		6	Product. Pening Comments Drider Typ Not: Hazay
Statuge loin: Sein Dispense tala Dispense tala CétMO-APO Billing formule Non Pass Thro Phile 6 no	egoty e sugh Cost Hon sp	~ ~	Communical Writian Dispense tro E Medical Or Dart dispense spepres	lon type: cology three e dats T \$ * *	v v er Phar v v	Drdes provily Drdes provily Provine Instal dosee 1	EUTIC.	AGENT			Product. Pening Order Typ Not: Hater
Staage korn. Keln Dispense cata HEMO-NPB Billing furmula Von Paas Thro Price 10.52	ngony sugh Cost \$9.52	> #*	Communicat Written Dispanse fro Dist dispense spepree	tion type: m lacation cology lines e date \$ + \$	v ser Phar v v	Drdes provin Endes provin Produce Vice PAP	EUTIC EUTIC	AGENT		5	Product. Penting Order Type Alert Hassey Re Intervent
Danago loint. Seán Dispense cata CHEMO-APP0 Billing furmula Non Pasa Phon \$0.52	agony sugh Cost \$0.52 wa misd	~ ~	Communicat Writen Dispersen fo Il Medicat Or Dart disperse ripspres	ion type: milication cology Breve e data \$ * *	v v v	Drdas provin Drdas provin Proties Proties With down () 1	enuc.	ADEMT			Product. Penting Comments Onder Type Not: Hastery Ris Intervent

Verifying Future Orders

To review and verify future orders placed by the provider, the future orders queue in the PPM will be monitored.

- Within PowerChart, perform the necessary clinical review by reviewing items such as pathology, lab results, etc., for new regimen orders.
- From Pharmacy Patient Monitor (PPM), select the appropriate view for future orders to verify.
- The process for verifying future orders is the same as verifying day of treatment orders using PPM, MedManager, and PowerChart, with the exception for a couple steps.
 - When verifying future orders, after Apply is selected in MedManager, the Future Order – Facility/Location Selection window displays.
 - Review the location listed is correct for where the medication will be dispensed from and update accordingly, if needed.
 - When verifying future orders in the Verify Intermittent Protocol window, review the details, make any updates as needed. It is important to zero out the labels before clicking OK.
- Otherwise, follow the normal process outlined above for using PPM and MedManager to continue verifying the future orders.

Pharn	nacy Patient Monitor
View:	Brewer Onc Future

M Future Order - Facility/Location Selection

NL Cancer Care Brewer Med Onc Treatment

NL CANCER CARE BREWER ME

Facility

Location

Treatment Periods

Initial doses:	
0	60'

Cancel

OK

×